Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Cannabidiol versus risperidone for treatment of recent-onset psychosis with comorbid cannabis use: study protocol for a randomized controlled clinical trial

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Associations between treatment with melatonin and suicidal behavior: a nationwide cohort study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Sleep-disordered breathing and cerebral small vessel disease-acute and 6 months after ischemic stroke

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Multiomics analysis of rheumatoid arthritis yields sequence variants that have large effects on risk of the seropositive subset

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Age estimation from sleep studies using deep learning predicts life expectancy

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. The sequences of 150,119 genomes in the UK Biobank

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

BACKGROUND: Cannabis use is an important risk factor for development of psychosis and further transition to schizophrenia. The prevalence of patients with psychosis and comorbid cannabis use (dual diagnosis) is rising with no approved specialized pharmacological treatment option. Cannabidiol, a constituent of the Cannabis sativa plant, has potential both as an antipsychotic and as a cannabis substituting agent. The aim of this study is to evaluate the efficacy of cannabidiol versus a first-choice second-generation antipsychotic (risperidone) in patients with early psychosis and comorbid cannabis use.

METHODS: The study is a phase II randomized, double-blinded, parallel-group, active-comparator clinical trial. We plan to include 130 patients aged between 18 and 64 years with a recent diagnosis of psychosis, comorbid cannabis use, and currently not treated with antipsychotics. The participants will be randomized to seven weeks of treatment with either cannabidiol 600 mg (300 mg BID) or risperidone 4 mg (2 mg BID). Participants will undergo clinical assessment after 1, 3, 5 and 7 weeks, telephone assessment the weeks in between, and a safety visit two weeks after end of treatment. The primary outcomes are cessation of cannabis use (self-reported) and psychotic symptom severity. The secondary outcomes include frequency and quantity of cannabis use, global illness severity, psychosocial functioning, subjective well-being, cognition, sleep, circadian rhythmicity, and metabolomics.

DISCUSSION: The results of this trial can potentially contribute with a new treatment paradigm for patients suffering from dual diagnosis.

TRIAL REGISTRATION: ClinicalTrials.gov , NCT04105231 , registered April 23rd, 2021.

OriginalsprogEngelsk
Artikelnummer404
TidsskriftBMC Psychiatry
Vol/bind21
Udgave nummer1
Sider (fra-til)1-11
Antal sider11
ISSN1471-244X
DOI
StatusUdgivet - 14 aug. 2021

Bibliografisk note

© 2021. The Author(s).

ID: 68506532